Ascendis Pharma to Present Breakthrough Findings at ESPE & ESE 2025
Ascendis Pharma A/S (Nasdaq: ASND) has announced plans to present cutting-edge data concerning its hypoparathyroidism, achondroplasia, and growth hormone deficiency (GHD) programs at the upcoming joint congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE). Set to take place in Copenhagen from May 10-13, 2025, this congress will serve as a platform for the latest advancements in rare endocrine disease treatment.
Insights into Clinical Trials and Presentations
During the congress, Ascendis will host a series of four oral presentations shedding light on their clinical trial results. Highlights will include:
- A comprehensive overview of 4-year efficacy and safety data from the Phase 2 PaTH Forward Trial focusing on TransCon PTH (palopegteriparatide) for adults with chronic hypoparathyroidism.
- Week 52 growth and bone morphometry data derived from the pivotal ApproaCH Trial of TransCon CNP (navepegritide) in children diagnosed with achondroplasia.
- Robust efficacy and safety data from the Phase 3 foresiGHt Trial involving TransCon hGH (lonapegsomatropin) for adults suffering from growth hormone deficiency.
Dr. Aimee Shu, Executive Vice President of Endocrine & Rare Disease Medical Science and Chief Medical Officer at Ascendis, expressed her excitement, stating, "We are thrilled to present promising data that underscore the clinical benefits of our innovative therapies to the key opinion leaders attending ESPE & ESE 2025."
Schedule of Presentations and Discussions
Throughout the congress, Ascendis Pharma will be engaged in numerous presentations and discussions:
Hypoparathyroidism
- Sunday, May 11, 09:55 - 10:25 CEST: Product Theater - Restoring Physiological Levels of PTH in Chronic Hypoparathyroidism
- Sunday, May 11, 16:55-17:55 CEST: Poster Hall - Estimating the Risk of Chronic Kidney Disease Progression in Chronic Hypoparathyroidism: A Retrospective Matched Cohort Study
- Monday, May 12, 13:00 - 14:30 CEST: Room D5 - Beyond Conventional Care: Redefining Treatment Success in Chronic Hypoparathyroidism
- Monday, May 12, 15:55-16:05 CEST: Room C2 - Long-Term Efficacy & Safety of Palopegteriparatide Treatment in Adults with Chronic Hypoparathyroidism: Findings from the Phase 2 PaTH Forward Trial
Achondroplasia
- Sunday, May 11, 15:55-17:25 CEST: Room C2 - Assessing HRQoL in Achondroplasia Across the Life Course
- Monday, May 12, 15:15-15:25 CEST: Room C2 - Effects of Navepegritide on Bone Morphometry in Children with Achondroplasia: Results from the ApproaCH Clinical Trial
- Tuesday, May 13, 15:05-15:15 CEST: Room D2 - Effects of Navepegritide on Growth in Children with Achondroplasia: Results from the ApproaCH Clinical Trial
Growth Hormone Deficiency
- Tuesday, May 13, 14:45-14:55 CEST: Room D2 - Results of the foresiGH Trial Support the Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults with GHD
Understanding Hypoparathyroidism, Achondroplasia, and GHD
Hypoparathyroidism is a significant endocrine disorder characterized by low parathyroid hormone (PTH) levels, affecting the body's ability to regulate calcium and phosphate effectively. This leads to numerous complications such as neuromuscular irritability and cognitive impairment. Most cases arise post-surgery, while others stem from autoimmune conditions.
On the other hand, achondroplasia is a genetic condition affecting bone growth, with wide-ranging systemic impacts beyond skeletal dysplasia, including muscular and neurological complications. It affects many individuals and requires ongoing medical attention to manage its effects through various life stages.
Growth hormone deficiency (GHD) can severely impact adults, leading to metabolic issues, increased body fat, impaired quality of life, and psychological challenges. The availability of innovative therapies like those offered by Ascendis Pharma presents a ray of hope for these conditions.
About Ascendis Pharma A/S
Ascendis Pharma is dedicated to leveraging its TransCon technology platform to offer innovative treatments aimed at improving patient outcomes. With a commitment to excellence anchored in their values of patients, science, and passion, Ascendis Pharma strives to develop therapies that are not only effective but also transformative. The company operates globally, with its headquarters situated in Copenhagen, Denmark.
Frequently Asked Questions
What is the focus of Ascendis Pharma's upcoming presentations?
Ascendis Pharma will present new data on hypoparathyroidism, achondroplasia, and growth hormone deficiency during ESPE & ESE 2025.
When and where will the congress occur?
The joint congress will take place from May 10-13, 2025, in Copenhagen.
Who will be presenting the findings?
A selection of presentations will be conducted by top experts, including Dr. Andrea Palermo and Dr. Leanne Ward, among others.
What conditions are being addressed by Ascendis Pharma?
Ascendis is focusing on conditions such as hypoparathyroidism, achondroplasia, and growth hormone deficiency.
How can I learn more about Ascendis Pharma's work?
For further details, you can visit Ascendis Pharma's official website, where they share comprehensive information about their innovative approaches and clinical studies.
